Philips strengthens strategic partnership with Sim&Cure to expand innovation in neurovascular therapy
- Dec 12, 2024
- 2 minute read
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the expansion of its strategic partnership with Sim&Cure, a leading provider of advanced digital solutions for neurovascular therapy. The partnership between the two companies started 5 years ago and is now entering into a next phase with the aim to further enhance Philips’ position in the interventional neuro domain by integrating Sim&Size™ software into Philips’ next-generation Image-Guided Therapy platform – Azurion. The advanced connection offers care providers a more seamless, intuitive and efficient workflow for treating complex brain aneurysms. In addition, the two companies will be developing new synergies through common projects to drive innovation into the future of cathlabs.
Brain aneurysms, which affect around 3-5% of the general population [1], pose a significant challenge due to their complexity and the precision required for device placement. Current planning and device selection methods involve multiple manual steps, increasing both procedure time and variability [2]. By integrating Sim&Size™ into Azurion, physicians can now simulate device placement, optimize selection, and guide deployment directly within the Azurion platform. This eliminates the need for separate software and hardware setups, enabling greater precision and efficiency in neurovascular procedures.
“The strengthened collaboration with Sim&Cure allows us to bring the power of simulation and image-guided therapy together in one platform, enhancing physician confidence and improving patient outcomes,” said Nicole Hermkens, VP Marketing IGT Systems at Philips. “By integrating Sim&Size™ into our Azurion platform, we are reducing complexity and variability in neurovascular procedures, ultimately helping to address the growing burden of brain aneurysms.”
Our combined offering allows clinicians to confidently plan and execute minimally invasive treatments, bringing the best of both companies’ innovations to bear for improved patient care.
Mathieu Sanchez
“We are excited to deepen our relationship with Philips and expand our joint impact in neurovascular therapy,” said Mathieu Sanchez, CEO of Sim&Cure. “Our combined offering allows clinicians to confidently plan and execute minimally invasive treatments, bringing the best of both companies’ innovations to bear for improved patient care.”
Philips is the global market leader in interventional suites. Worldwide, Philips’ image-guided therapy solutions help treat one patient every second, and for many of those, the Azurion platform is being used. Since its launch in 2017, Azurion has been used to treat more than five million patients in over 90 countries. Earlier this year, Philips introduced the latest version of Azurion, a biplane model designed specifically to support neuro interventions. It features enhanced 2D and 3D imaging capabilities, improved C-arm rotation flexibility, and optimized workflow features to help clinicians perform complex neurovascular procedures more effectively and efficiently.
With this strengthened partnership, Philips continues to lead in stroke care and interventional neuro therapies. This collaboration reflects Philips’ ongoing commitment to offering an integrated suite of solutions that support the entire stroke care pathway, from diagnosis and treatment to post-procedure monitoring.
